Targeted protein degradation (TPD) provides unprecedented opportunities for drug
discovery. While the proteolysis-targeting chimera (PROTAC) technology has already …

Carbohydrates are essential mediators of many processes in health and disease. They
regulate self-/non-self-discrimination, are key elements of cellular communication, cancer …

Selective protein degradation platforms have afforded new development opportunities for
therapeutics and tools for biological inquiry. The first lysosome-targeting chimeras (LYTACs) …

Two decades of research on RNA interference (RNAi) have transformed a breakthrough
discovery in biology into a robust platform for a new class of medicines that modulate mRNA …

Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy. Most
TPD technologies use the ubiquitin–proteasome system, and are therefore limited to …

Covalent attachment of a synthetic triantennary N-acetylagalactosamine (GalNAc) ligand to
chemically modified siRNA has enabled asialoglycoprotein (ASGPR)-mediated targeted …

Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the
accessible binding sites to achieve prolonged occupancy and influence protein functions …

Nanoparticle-based delivery systems have contributed to the recent clinical success of RNA
therapeutics, including siRNA and mRNA. RNA delivery using polymers has several distinct …

Cell surface protein–carbohydrate interactions are essential for tissue-specific recognition
and endocytosis of viruses, some bacteria and their toxins, and many glycoproteins. Often …

Lysosome‐targeting chimeras (LYTACs) are an emerging therapeutic modality that
effectively degrade cancer cell membranes and extracellular target proteins. In this study, a …